stockportfolio.pro
Adlai Nortye Ltd. (ANL)
Healthcare · Biotechnology · NasdaqGM
Adlai Nortye Ltd. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $5.00M | $0 | $5.00M |
| Gross profit | — | — | — | — |
| Net income | $-58.79M | $-109.23M | $-51.87M | $-35.53M |
| Net margin | — | -2184.6% | — | -710.6% |
Source: Adlai Nortye Ltd. SEC filings (10-K).
Explore 4 years of Adlai Nortye Ltd. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ANL in your portfolio →
Adlai Nortye Ltd. financial history by metric
About Adlai Nortye Ltd.
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.
Adlai Nortye Ltd. — frequently asked questions
What is Adlai Nortye Ltd.'s revenue?
Adlai Nortye Ltd. (ANL) reported revenue of $5.00M for fiscal year 2025, according to its SEC filings.
Is Adlai Nortye Ltd. profitable?
No — ANL reported a net loss of $-35.53M in fiscal 2025.
What is ANL's P/E ratio?
Adlai Nortye Ltd. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Adlai Nortye Ltd. have?
As of fiscal year 2025, ANL carried roughly $24.58M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Adlai Nortye Ltd.'s market cap?
Adlai Nortye Ltd. (ANL) has a market capitalization of about $657.50M, based on the latest data in our nightly-refreshed cache.
When does Adlai Nortye Ltd.'s fiscal year end?
ANL's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Adlai Nortye Ltd.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.